Health Catalyst (NASDAQ:HCAT) Given Equal Weight Rating at Stephens

Stephens reiterated their equal weight rating on shares of Health Catalyst (NASDAQ:HCAT) in a report released on Thursday morning,Benzinga reports. The brokerage currently has a $7.00 target price on the stock.

HCAT has been the topic of a number of other reports. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective on the stock in a research report on Wednesday, January 8th. Royal Bank of Canada reduced their price objective on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 15th. Canaccord Genuity Group reduced their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 21st. Wells Fargo & Company lowered their target price on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. Finally, Piper Sandler reduced their target price on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Health Catalyst has an average rating of “Moderate Buy” and an average target price of $9.45.

Health Catalyst Trading Down 13.0 %

Shares of HCAT opened at $4.30 on Thursday. The stock has a market capitalization of $261.46 million, a P/E ratio of -3.18 and a beta of 1.34. The firm has a fifty day simple moving average of $6.03 and a two-hundred day simple moving average of $7.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a twelve month low of $3.76 and a twelve month high of $9.24.

Insider Activity

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the transaction, the insider now owns 236,950 shares of the company’s stock, valued at approximately $2,118,333. The trade was a 3.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96. Following the sale, the insider now directly owns 98,702 shares in the company, valued at approximately $777,771.76. The trade was a 6.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 87,610 shares of company stock valued at $664,043 over the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. First Light Asset Management LLC boosted its holdings in shares of Health Catalyst by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company’s stock worth $37,055,000 after buying an additional 944,631 shares during the last quarter. Alyeska Investment Group L.P. raised its position in Health Catalyst by 74.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock worth $14,277,000 after acquiring an additional 861,150 shares during the period. Fred Alger Management LLC purchased a new position in shares of Health Catalyst during the 3rd quarter worth $6,858,000. Portolan Capital Management LLC purchased a new position in shares of Health Catalyst during the 3rd quarter worth $5,402,000. Finally, Kennedy Capital Management LLC grew its position in shares of Health Catalyst by 42.7% during the 4th quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company’s stock valued at $13,369,000 after acquiring an additional 565,445 shares during the period. 85.00% of the stock is owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.